1.
Report Overview
1.1.
Report Description
1.2.
Research Methods
1.3.
Research Approaches
2.
Executive Summary
3.
Market Overview
3.1.
Introduction
3.2.
Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3.
PEST-Analysis
3.4.
Porter's Diamond Model for the United
States Urinary Tract Infection Market
3.5.
IGR-Growth Matrix Analysis
3.6.
Competitive Landscape in the United
States Urinary Tract Infection Market
4.
United States Urinary Tract
Infection Market by Drug Class
4.1.
Quinolones
4.2.
Aminoglycosides
4.3.
β-lactam
4.4.
Azoles
4.5.
Other Drug Class
5.
United States Urinary Tract
Infection Market by Clinical Indications
5.1.
Cystitis
5.2.
Urethritis
5.3.
Pyelonephritis
5.4.
Other Clinical Indications
6.
United States Urinary Tract
Infection Market by End User
6.1.
Hospitals
6.2.
Self-administered
6.3.
Other End Users
7.
Company Profiles
7.1.
Manufacturer's & Suppliers
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.1.4. Company 4
7.1.5. Company 5
7.2.
Dealer's / Distributor's Profile
7.2.1. Dealer's /
Distributor's 1
7.2.2. Dealer's /
Distributor's 2
7.2.3. Dealer's /
Distributor's 3
7.2.4. Dealer's /
Distributor's 4
7.2.5. Dealer's /
Distributor's 5
7.2.6. Dealer's /
Distributor's 6
7.2.7. Dealer's /
Distributor's 7
7.2.8. Dealer's /
Distributor's 8
7.2.9. Dealer's /
Distributor's 9
7.2.10.
Dealer's / Distributor's 10
1.
Report Overview
1.1.
Report Description
1.2.
Research Methods
1.3.
Research Approaches
2.
Executive Summary
3.
Market Overview
3.1.
Introduction
3.2.
Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3.
PEST-Analysis
3.4.
Porter's Diamond Model for the United
States Urinary Tract Infection Market
3.5.
IGR-Growth Matrix Analysis
3.6.
Competitive Landscape in the United
States Urinary Tract Infection Market
4.
United States Urinary Tract
Infection Market by Drug Class
4.1.
Quinolones
4.2.
Aminoglycosides
4.3.
β-lactam
4.4.
Azoles
4.5.
Other Drug Class
5.
United States Urinary Tract
Infection Market by Clinical Indications
5.1.
Cystitis
5.2.
Urethritis
5.3.
Pyelonephritis
5.4.
Other Clinical Indications
6.
United States Urinary Tract
Infection Market by End User
6.1.
Hospitals
6.2.
Self-administered
6.3.
Other End Users
7.
Company Profiles
7.1.
Manufacturer's & Suppliers
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.1.4. Company 4
7.1.5. Company 5
7.2.
Dealer's / Distributor's Profile
7.2.1. Dealer's /
Distributor's 1
7.2.2. Dealer's /
Distributor's 2
7.2.3. Dealer's /
Distributor's 3
7.2.4. Dealer's /
Distributor's 4
7.2.5. Dealer's /
Distributor's 5
7.2.6. Dealer's /
Distributor's 6
7.2.7. Dealer's /
Distributor's 7
7.2.8. Dealer's /
Distributor's 8
7.2.9. Dealer's /
Distributor's 9
7.2.10.
Dealer's / Distributor's 10